Presentation is loading. Please wait.

Presentation is loading. Please wait.

Federal Agency for Medecines and Health Products Federal Agency for Medicines and Health Products (FAMHP) FAMHP/DLT/ 28.01.2010 Lambot Damien Materiovigilance.

Published byDelilah Nash Modified over 9 years ago

Similar presentations

Presentation on theme: "Federal Agency for Medecines and Health Products Federal Agency for Medicines and Health Products (FAMHP) FAMHP/DLT/ 28.01.2010 Lambot Damien Materiovigilance."— Presentation transcript:

1 Federal Agency for Medecines and Health Products Federal Agency for Medicines and Health Products (FAMHP) FAMHP/DLT/ 28.01.2010 Lambot Damien Materiovigilance Medical Device Vigilance 28.01.2010 1

2 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 2 Medical Device Vigilance 1.Definitions and legal basis 1.1. Organigramme 1.2. Legal basis 1.3. Definitions 1.3.1. Materiovigilance 1.3.2. Medical Device 1.3.3. Corrective Action 1.3.4. Field Safety Corrective Action (FSCA) 1.3.5. Field Safety Notice (FSN) 2. What shall be notify? 3. Who should be notify? 4. When must incidents be notified? 5. How should incidents be notified? 5.1. Users 5.2. Manufacturers, distributors, authorised representatives

3 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 3 1. Definitions and legal basis Medical Device Vigilance

4 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 4 1. Definitions and legal basis 1.1 Organigramme DG PRE authorisation DG POST authorisation DG INSPECTION R&D Division (human) Marketing Authorisation Division (human) Medicines for Veterinary use Division Assessors Division Marketing Authorisation Division Variations & Renewals Vigilance Division (pharmaco, materio, haemo, bio) Health Products Division Proper Use Division “Industry” Division “Dispensing” Division Control Policy Division SOE-USE Special Investigation Unitd’enquête

5 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 5 1. Definitions and legal basis 1.2 Legal basis Royal decrees: Royal decree 18/03/1999 (art. 11): Medical Device (MD) Royal decree 15/07/1997 (art. 12): Active Implantable Medical Device (AIMD) European Directives: Directive 93/42/EEC (MD) Directive 90/385/EEC (AIMD) Other: Guideline: MEDDEV 2.12-1 rev 6: not legally binding

6 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 6 1. Definitions and legal basis 1.3 Definitions 1.3.1 Materiovigilance The purpose of materiovigilance is to study and follow incidents that might result from using medical devices. It enables dangerous devices to be withdrawn from the market and to eliminate faults in medical devices with the intention of constantly improving the quality of devices and providing patients and users with increased safety. Materiovigilance only refers to medical devices whereas pharmacovigilance refers to medicines.

7 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 7 1. Definitions and legal basis 1.3.2 Medical Device Medical device is defined as any instrument, equipment, material or other article used on its own or jointly, including software required for it to function correctly, which is intended by the manufacturer to be used on humans for the following purposes : for diagnostic, prevention, control, treating or diminishing an illness for diagnostic, control, treating, for diminishing or compensating an injury or handicap, for studying, replacing or modifying part of the anatomy or a physiological process for mastering conception and whose principal intended action in or on the human body is not obtained by pharmacological or immunological means or by metabolism but whose function can be assisted in such a way. More definition in the art. 1 of the law : accessory, active medical device, active implantable medical device, custom made device.

8 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 8 1. Definitions and legal basis 1.3.3: Corrective Action: Action to eliminate the cause of a potential non-conformity or other undesirable situation. NOTE1: There can be more than one cause for non- conformity. NOTE 2: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence.

9 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 9 1. Definitions and legal basis 1.3.4.: Field Safety Corrective Action (FSCA): A FIELD SAFETY CORRECTIVE ACTION is an action taken by a MANUFACTURER to reduce a risk of death or serious deterioration in the state of health associated with the use of a MEDICAL DEVICE that is already placed on the market. Such actions should be notified via a FIELD SAFETY NOTICE. The FSCA may include - the return of a MEDICAL DEVICE to the supplier; - device modification; - device exchange; - device destruction; - retrofit by purchaser of MANUFACTURER's modification or design change; - advice given by MANUFACTURER regarding the use of the device (e.g. where the device is no longer on the market or has been withdrawn but could still possibly be in use) A device modification can include: - permanent or temporary changes to the labelling or instructions for use; - software upgrades including those carried out by remote access; - For implantable devices it is often clinically unjustifiable to explant the device. Corrective action taking the form of special patient follow-up, irrespective of whether any affected un-implanted devices remain available for return, constitutes FSCA.

10 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 10 1. Definitions and legal basis 1.3.5. Field Safety Notice (FSN) A communication to customers and/or USERs sent out by a MANUFACTURER or its representative in relation to a Field Safety Corrective Action.

11 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 11 Medical Device Vigilance 2. What shall be notify?

12 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 12 2.What shall be notify? - any dysfunction or any change of the characteristics and/or performance of a device, and any inadequacy in the labelling or instructions, which might lead to or have led to death or serious relapse in the state of health of a patient, a user or a third party. - any technical or medical reason related to the characteristics or performance of a device for reasons shown in the previous paragraph and having led to the systematic withdrawal from the market by a manufacturer of devices of the same type.

13 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 13 2.What shall be notify? Not only must one notify serious incidents which have actually taken place but also the cases where there was a risk of a serious incident but that incident was avoided thanks to the attention and action of the relevant people.

14 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 14 2.What shall be notify? Definition of an serious incident: An incident is considered serious if it has one of the following consequences or could have had such a consequence: - death, an illness or a handicap - a permanent lesion of a function or structure - the need for a medical or surgical operation - for a prolongation of a surgical operation - incorrect results of examinations leading to an incorrect diagnostic or treatment

15 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 15 2.What shall be notify? Examples: 1. An infusion pump stops, due to a malfunction, but gives an appropriate alarm (e.g. in compliance with relevant standards) and there was no injury to the patient.  do not need to be reported. 2. An infusion pump stops, due to a malfunction of the pump, but fails to give an appropriate alarm; there is no patient injury. This should be reported as in a different situation it could have caused a serious deterioration in state of health.

16 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 16 2.What shall be notify? 3. An aortic balloon catheter leaked because of inappropriate handling of the device in use, causing a situation which was potentially dangerous to the patient. It is believed that the inappropriate handling was due to inadequacies in the labelling. This incident should be reported. 4. A defect is discovered in one (hitherto unopened) sample of a batch (lot) of a contact lens disinfecting agent that could lead to incidence of microbial keratitis in some patients. The MANUFACTURER institutes a FSCA of this batch. The FSCA should be reported.

17 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 17 2.What shall be notify? 5. Loss of sensing after a pacemaker has reached end of life. Elective replacement indicator did not show up in due time, although it should have according to device specification. This INCIDENT should be reported. 6. The premature revision of an orthopedic implant is required due to loosening. Although no cause is yet determined, this INCIDENT should be reported.

18 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 18 Medical Device Vigilance 3. Who should be notify?

19 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 19 3. Who should notify? Not only the manufacturers or their representatives but also persons distributing devices, notified bodies, practitioners and people responsible for receiving and/or delivering devices should all signal incidents to : Federal Agency for Medicines and Health Products – Vigilance Division. Email address : meddev@fagg-afmps.be

20 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 20 Medical Device Vigilance 4. When must incidents be notified?

21 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 21 4. When must incidents be notified? Incidents must be notified as quickly as possible using the quickest means possible. Incidents that have led to death or serious injury must be notified immediately.

22 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 22 Medical Device Vigilance 5. How should incidents be notified?

23 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 23 5. How should incidents be notified? 5.1 User (pharmacist, doctors)  www.fagg-afmps.be www.fagg-afmps.be  Human use  Medical devices and their accessories  How should incidents be notified

24 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 24 5. How should incidents be notified?  http://ec.europa.eu/enterprise/sectors/medical- devices/index_en.htm  Market surveillance and vigilance  Reference documents  Guidance  2.12 Market surveillance (Manufacturer Incident Report and Field safety Corrective Action) 5.2. Manufacturers, distributors, authorised representatives,…

25 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 25

26 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 26

27 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 27

28 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 28 5. How should incidents be notified?

29 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 29 5. How should incidents be notified? Documents to provide (FSCA): - The traceability data for Belgium (list of Belgian Customers, with quantities provided per lot number). - The model letter in our national languages (FSN) - Once available evidence that the users have received the letter and reconciliation data.

30 FAMHP/DLT 28.01.2010 Federal Agency for Medecines and Health Products 30 Links : Federal Agency for Medecines and Health Products : http://www.fagg- afmps.be/en/human_use/health_products/medical_devices_accessories/materiovigilance/index.jsp Belgian legislation: http://www.fagg-afmps.be/fr/humain/produits_de_sante/dispositifs_medicaux/legislation/index.jsp Market Surveillance and Vigilance on European Commission Web Site: http://ec.europa.eu/enterprise/sectors/medical-devices/market-surveillance-vigilance/index_en.htm Forms: -Distributor / Manufacturer /Authorized representative / …:  FSCA: http://ec.europa.eu/enterprise/sectors/medical- devices/files/meddev/report_form_field_safety_corrective_action_en.dochttp://ec.europa.eu/enterprise/sectors/medical- devices/files/meddev/report_form_field_safety_corrective_action_en.doc  Incident: http://ec.europa.eu/enterprise/sectors/medical- devices/files/meddev/report_form_manufacturers_incident_report_en.dochttp://ec.europa.eu/enterprise/sectors/medical- devices/files/meddev/report_form_manufacturers_incident_report_en.doc - User: http://www.fagg- afmps.be/fr/binaries/Copie%20de%20vigilance%20report%20%20FR%20vers.041104_tcm291- 27060_tcm291-27060.xlshttp://www.fagg- afmps.be/fr/binaries/Copie%20de%20vigilance%20report%20%20FR%20vers.041104_tcm291- 27060_tcm291-27060.xls Email address of Health Product Division and Medical Device Vigilance Unit: meddev@fagg-afmps.be

Download ppt "Federal Agency for Medecines and Health Products Federal Agency for Medicines and Health Products (FAMHP) FAMHP/DLT/ 28.01.2010 Lambot Damien Materiovigilance."

Similar presentations

And the provisions of….. the Medical Devices Regulations Medical Devices Agency.

And the provisions of….. the Medical Devices Regulations Medical Devices Agency.
Medical Devices The current legislative and administrative structure.

Medical Devices The current legislative and administrative structure.
Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010

Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010
Australian Guidance Document Number xx Cathy Thomas Professional Representation OT Australia WA.

Australian Guidance Document Number xx Cathy Thomas Professional Representation OT Australia WA.
Market surveillance. Internal market Enforcement of Community legislation is an obligation on Member States: Article 10 of the EC Treaty requires Member.

Market surveillance. Internal market Enforcement of Community legislation is an obligation on Member States: Article 10 of the EC Treaty requires Member.
Susan Best, NRL, Australia WHO post-market surveillance for In Vitro Diagnostic Devices (IVD)

Susan Best, NRL, Australia WHO post-market surveillance for In Vitro Diagnostic Devices (IVD)
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent

Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
JOB FUNCTION EVALUATION Lowering Your Accident Costs.

JOB FUNCTION EVALUATION Lowering Your Accident Costs.
S4: Market Surveillance 2012-10-31 1 Physikalisch-Technische Bundesanstalt Session 4: Market surveillance Peter Ulbig, Harry Stolz Belgrade, 31 October.

S4: Market Surveillance Physikalisch-Technische Bundesanstalt Session 4: Market surveillance Peter Ulbig, Harry Stolz Belgrade, 31 October.
OHSAS 18001: Occupational health and safety management systems - Specification Karen Lawrence.

OHSAS 18001: Occupational health and safety management systems - Specification Karen Lawrence.
RC14001 ® Update GPCA Responsible Care Committee September 23, 2013.

RC14001 ® Update GPCA Responsible Care Committee September 23, 2013.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.

External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
CE marking Catriona Blake Team Manager, Imaging, acute and community care.

CE marking Catriona Blake Team Manager, Imaging, acute and community care.
Product Definition Chapter 4. What is a Medical Device? FDA: “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,

Product Definition Chapter 4. What is a Medical Device? FDA: “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
© 2009 Michigan State University licensed under CC-BY-SA, original at Corrective Action.

© 2009 Michigan State University licensed under CC-BY-SA, original at Corrective Action.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.

Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.

Regulatory Update Ellen Leinfuss SVP, Life Sciences.
U D T Workshop on the Pressure Equipment Directive, Warsaw 24-26 June 2004 INTERFACES BETWEEN NATIONAL LEGISLATION AND DIRECTIVE 97/23/EC SYSTEM OF ENSURING.

U D T Workshop on the Pressure Equipment Directive, Warsaw June 2004 INTERFACES BETWEEN NATIONAL LEGISLATION AND DIRECTIVE 97/23/EC SYSTEM OF ENSURING.
Janine Webster (Medical Device Training Officer)

Janine Webster (Medical Device Training Officer)

Similar presentations

Ads by Google